$XBI $70.33 | +1.3%
Table of Contents:
Covid Updates
$NVAX -8.6% Novavax Files in the European Union for Expanded Conditional Marketing Authorization of COVID-19 Vaccine as a Booster in Individuals Aged 18 and Over.
Pipeline Updates
$AUPH +3.4% Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress.
$VERA +3.5% Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress.
$KRYS +3.7% Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
$ATHX -65.5% Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE MultiStem Ischemic Stroke Study
$ASLN -1.4% ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting
$BBIO +3.0% bridgebio pharma affiliate phoenix tissue repair announces positive results from phase 2 trial of ptr-01, a protein replacement therapy for the treatment of recessive dystrophic epidermolysis bullosa (rdeb)
$EIGR -0.2% Eiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
$KPTI +3.0% Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
$TXMD +36.6% TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
$KDNY +8.4% CHINOOK THERAPEUTICS PRESENTS DATA FROM ATRASENTAN PHASE 2 AFFINITY IGA NEPHROPATHY (IGAN) PATIENT COHORT AND EVOTEC COLLABORATION AT THE 59TH EUROPEAN RENAL ASSOCIATION (ERA) CONGRESS 2022
$AUPH +3.4% Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
$RDUS +7.0% Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
$EVFM -63.2% Evofem Biosciences Announces Proposed Public Offering & Pricing
$CRTX -6.1% Cortexyme Successfully Completes Acquisition of Novosteo
$ZYME +3.0% Zymeworks’ Board Of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
Posted by DV/FS